发明名称 Dosing and development of antimicrobial and antiviral drugs determined by restriction of resistant mutant selection
摘要 The invention is based on the discovery that, for many drugs (e.g., antiviral or antimicrobial drugs such as antifungal or antibacterial drugs, including bacteriocidal or bacteriostatic drugs) and many pathogen strains (e.g., viral, fungal, or bacterial pathogens), a concentration of drug can be identified at which drug-resistant mutant pathogen strains are not selected. This concentration is herein referred to as the "mutant prevention concentration" (MPC). Maintaining serum concentrations of the drug above the MPC throughout a course of treatment should severely restrict selection of drug-resistant mutants. Additionally, it is discovered that drug-resistant mutant pathogens are selected exclusively within a drug concentration window, termed the "mutant selection window" (MSW). A quantitative expression of this window, which we call the "window index" (WI), is defined as the ratio of the MPC to the MIC. The window index is characteristic of a given drug and a given pathogen.
申请公布号 US2002004220(A1) 申请公布日期 2002.01.10
申请号 US20010901296 申请日期 2001.07.09
申请人 THE PUBLIC HEALTH RESEARCH INSTITUTE OF THE CITY OF NEW YORK, INC. 发明人 DONG YUZHI;DRLICA KARL;ZHAO XILIN
分类号 C12Q1/18;(IPC1-7):C12Q1/18;C12Q1/70 主分类号 C12Q1/18
代理机构 代理人
主权项
地址